TY - JOUR
T1 - Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia
AU - Vojdeman, Fie J.
AU - Herman, Sarah E. M.
AU - Kirkby, Nikolai
AU - Wiestner, Adrian
AU - van T' Veer, Mars B.
AU - Tjønnfjord, Geir E.
AU - Itälä-Remes, Maija A.
AU - Kimby, Eva
AU - Farooqui, Mohammed Z.
AU - Polliack, Aaron
AU - Wu, Ka Lung
AU - Doorduijn, Jeanette K.
AU - Alemayehu, Wendimagegn G.
AU - Wittebol, Shulamiet
AU - Kozak, Tomas
AU - Walewski, Jan
AU - Abrahamse-Testroote, Martine C. J.
AU - van Oers, Marinus H. J.
AU - Geisler, Christian H.
AU - Niemann, Carsten U.
PY - 2017
Y1 - 2017
N2 - CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL
AB - CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL
U2 - https://doi.org/10.1080/10428194.2017.1285027
DO - https://doi.org/10.1080/10428194.2017.1285027
M3 - Article
C2 - 28278728
SN - 1042-8194
VL - 58
SP - 2356
EP - 2362
JO - Leukemia & lymphoma
JF - Leukemia & lymphoma
IS - 10
ER -